EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis

Yongsheng Zheng iD, Jianian Hu iD, Chong Sun, Chongbo Zhao iD, Jie Lin

European Journal of Neurology · 2023

DOI: 10.1111/ene.15857 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Yongsheng Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Treatment options for chronic inflammatory demyelinating polyneuropathy (CIDP) are intravenous immunoglobulin, plasmapheresis, corticosteroids and immunosuppressive drugs. However, a substantial proportion of patients with CIDP remain refractory to treatment and develop severe functional disability. A systematic review and a meta‐analysis of the efficacy of hematopoietic stem cell transplantation (HSCT) treatment in refractory CIDP patients was performed.

Methods

The study is based on queries in the PubMed, Cochrane Central Register of Controlled Trials, Embase, Web of Science and clinicaltrials.gov databases on 4 December 2022. Articles that met our eligibility criteria were included after screening. Patients' characteristics, treatment regime and outcome measures were extracted.

Results

Eighty‐nine patients in 11 studies were included. The pooled estimate of responsiveness amongst the four included studies was 87.04% (95% confidence interval 66.7%–99.5%) and the pooled estimate of freedom of all immune modulating or suppressive drugs was 80.75% (95% confidence interval 71.2%–90.2%).

Conclusion

This meta‐analysis and systematic review suggested that HSCT can be effective in the treatment of refractory CIDP. Whilst there are risks involved, HSCT may be a beneficial and viable therapy for refractory CIDP when carefully evaluated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingHematopoietic Stem Cell TransplantationHumansImmunoglobulins, IntravenousImmunosuppressive AgentsAdrenal Cortex Hormones

Stichwörter der Autor:innen

CIDPautoimmune diseasehematopoietic stem cell transplantationrefractorytreatment

Substanzen

Immunoglobulins, IntravenousImmunosuppressive AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
  • National Center for Neurological Disorders (NCND), Shanghai, China.
  • Huashan Rare Disease Center, Huashan Hospital Fudan University, Shanghai, China.

ORCID-Profile: Yongsheng Zheng, Jianian Hu, Chongbo Zhao

Zitieren

APA

Zheng, Y., Hu, J., Sun, C., Zhao, C., & Lin, J. (2023). Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis. European Journal of Neurology. https://doi.org/10.1111/ene.15857

Vancouver

Zheng Y, Hu J, Sun C, Zhao C, Lin J. Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis. European Journal of Neurology. 2023. doi:10.1111/ene.15857

BibTeX
@article{Zheng2023,
  author = {Zheng, Yongsheng and Hu, Jianian and Sun, Chong and Zhao, Chongbo and Lin, Jie},
  title = {Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15857}
}
Kostenlos starten →